Media about us

13 November / 2020

Sintez OJSC (a Kurgan-based pharmaceutical company controlled by AFK Sistema and Rostech's National Immunobiological Company) has published its financial statements for the first nine months of 2020.

Sintez OJSC (a Kurgan-based pharmaceutical company controlled by AFK Sistema and Rostech's National Immunobiological Company) has published its financial statements for the first nine months of 2020. The Company's revenue is up 42% on the same period from last year, totaling RUB 10.36 billion. The Company's press service announced a 45% increase in net profit, up to RUB 1.14 billion.

Sintez OJSC's sales to hospitals from January through September nearly doubled in money terms, while retail sales were up 29%. The best-selling items were the over-the-counter analgesics Diclofenac and Ibuprofen, as well as the prescription antibiotic Ceftriaxone. According to the Binnopharm Group CEO Rustem Muratov, the third quarter was a very hectic time for Sintez, as the Company's production sites were operating at full capacity in three shifts to meet the increase in demand from medical facilities and pharmacies because of the pandemic. The output of antibiotics increased by an average of 30% during this period.

https://www.kommersant.ru/doc/4573200